Mary Caffrey

Results presented at the American Heart Association in Chicago provided the strongest evidence to date on what heart failure specialists have discussed for several years now: the possibility that SGLT2 inhibitors might be used to prevent heart failure in patients with type 2 diabetes.

The announcement is an about-face from earlier efforts that scrapped a cardiac care bundled payment program originally developed during the Obama administration.

The study examined several social factors that can affect health outcomes when patients are hospitalized for cardiovascular events.

Developing a predictive model can identify which patients could be at risk of developing an opioid use disorder and allow health systems to prevent this from happening.

The report, more than a year in the making, comes at the start of Diabetes Awareness Month.

The label change includes data from the LEADER trial, which showed that the same active ingredient, liraglutide, reduced major cardiovascular events when given at a lower dose.

The analysis comes amid a debate set off when CVS Caremark announced that it would allow self-funded insurers to exclude drugs that entered the market above $100,000 per quality-adjusted life year.

Cardiovascular outcomes trials have changed type 2 diabetes drug development and added to the knowledge base, but some think these giant studies make therapies too costly and discourage innovation.

A new session at the Academy for Managed Care Pharmacy Nexus 2018 allowed for sharing ideas that have recently been put into practice.

A life-saving therapy is challenging to administer and poses financial risks for patients and institutions alike. Speakers at the Academy of Managed Care Pharmacy Nexus 2018 address some approaches to paying for it while CMS develops long-term policies.

Program audits are the chief tool used to evaluate how well health plans deliver care to an ever-growing share of Medicare's 60 million beneficiaries.

The combination therapy lets patients take a single pill once a day for treatment, which leads to improved adherence. Results of the study were presented at the Academy of Managed Care Pharmacy Nexus 2018 in Orlando, Florida.

A major bill to curb opioid abuse and the Trump administration's blueprint to rein in drug prices highlighted a busy year in the legislative and regulatory arena for the Academy of Managed Care Pharmacy.

Express Scripts' Aimee Tharaldson, PharmD, gave her overview of the specialty pharmacy pipeline for 2019 and beyond at the Academy of Managed Care Pharmacy Nexus 2018 meeting in Orlando, Florida.

The breach comes as the Trump administration hopes to rely more heavily on professionals to assist consumers during open enrollment.

Researchers have created a database that shows how 409 different tumor cells respond to 122 therapies, which will allow clinical trials to proceed for this aggressive blood cancer.

Finding a place for value-based payment with the fast paced innovation in oncology.

The idea for putting drug prices in TV ads was part of the blueprint, American Patients First. The pharmaceutical industry opposes the plan on First Amendment grounds.

As CareMore Health touts success in keeping Medicaid patients out of the emergency department, a separate report shows lack of access to Medicaid keeps the poor in many states from seeking care.

The analysis of data from EMPA-REG OUTCOME arrives as the FDA weighs the future of these large trials.

The deal could lead to the transformation of CVS' drug stores into retail medical centers. The American Medical Association opposes the plan.

Research at the University of Washington is exploring the possibility of triggering one gene to take over the function of another with a common mutation that triggers acute lymphoblastic leukemia.

Patient preference should be considered because medications don't work if adherence is poor, the experts noted.

The dual inhibitor first blocks 2 kinases that are known to aid the growth of malignant B cells, and then it disrupts the microenvironment that supports tumor growth.

Pharmacy benefit managers (PBMs) will have to disclose some information about their compensation and relationships with payers.

The Institute for Value-Based Medicine travels to New York City to learn how technology and trust are key to making the leap to two-sided risk.

For 2017, New Jersey's largest insurer made particularly good progress in certain diabetes measures and in cancer screenings.

James P. Allison, PhD, and Tasuku Honjo, MD, PhD, led the basic science experiments that showed the potential of checkpoint inhibitors, creating a fourth pillar in the treatment of cancer.

POSTERS AT THE 2018 American Association of Diabetes Educators (AADE) Annual Conference covered updates on new therapies and technology, strategies to help patients overcome fear of using insulin, and innovations in diabetes self-management education and support. Following are a few snapshots of the research presented at AADE.

Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.